CM – Creso posts record sales growth for the second quarter in a row


We track your page views and clicks so that we can continue to improve the website for our users.

Creso Pharma Limited (ASX: CPH, FRA: 1X8) achieved record sales growth with its Swiss operations and wholly Canadian subsidiary Mernova Medicinal Inc. in the June quarter.

This has contributed to the company’s growing sales profile , which has benefited from multiple orders from different provinces, underscoring the increased demand for Mernova’s products in Canada.

To date, Creso Pharma has total sales of $ 1,715,933 in the June quarter, an increase of $ 24 % compared to the previous quarter (Q1 of the year 2021: 1,385,000 AUD) and an increase of 451% compared to the corresponding previous quarter (Q2: 311,353 AUD).

The constant growth from quarter to quarter is due to the strong demand for the Craft cannabis products from Mernova and the CBD products for animal and human health from Creso Pharma underpinned.

This creates trust in the scalable, recurring order The company’s rate model that provides the broader group with increasing visibility and revenue predictability.

Mernova has total revenues of A $ 1,040,454 from purchases in various provinces including Nova Scotia Liquor Corporation (NSLC), New Brunswicks sole legal cannabis retailer, and Yukon Liquor Corporation for their pre-roll range of Ritual Green and Ritual Sticks.

The strong sales performance was driven by increasing demand for CBD animal and human health products from Creso Pharma Supported.

Creso Pharma’s Swiss operations have contributed around 469 083 CHF (675 479 AUD) to total quarterly sales growth to date through the sale of the company’s high-quality CBD products for animals and humans.

The most recent sales growth is in line with the company’s strategy of increasing sales in existing key markets, the international expansion n to continue and introduce new products.

Creso Pharma has a positive outlook for sales growth and believes that the merger of Red Light Holland (RLH) could potentially offer several new short term entries and expansion opportunities

There were also positive news from the regulatory front as Connecticut became the nineteenth state in the US to allow recreational cannabis use.

The state passed a law on Tuesday, June 22, 2021, allowing people 21 and older to possess and use marijuana starting July 1, 2021.

The law change is expected to lay the groundwork for a new cannabis industry in the state.

Government officials believe that retail sales of recreational Cannabis in the state will begin in 2022.

There has been movement in California and Senate Bill 519 (SB519) is now through the Committee on Public Si Safety has been passed by the California State Assembly, which is another crucial step in the process of getting the legislation passed.

SB519 suggests that a wide range of psychedelic substances, including psilocybin, be legal for adults over the age of 21 to use and become as well as eradicating previous use and possession crimes.

The bill was introduced to advance a more health-centric approach to the use of psychedelic compounds and to address the current mental health crisis in the United States. It also marks the ongoing push towards acceptance of psychedelic compounds as an alternative route of treatment.

This offers Creso Pharma and Red Light Holland another great market opportunity ahead of the possible merger to form The HighBrid Lab.

Both parties are currently considering go- to-market strategies and ways to expand Mernova’s offerings to advance entry into US markets.

The US is expected to become the world’s largest cannabis market, valued at $ 41 billion by 2025 .

With its business operations and upcoming corporate developments, Creso Pharma is very well positioned to benefit from this emerging market and unlock considerable value for shareholders.

On the excellent sales growth and the factors that are particularly important in the The non-executive chairman said that the planned merger is expected to provide sustained momentum e Adam Blumenthal: « The recent sales growth across the group is very encouraging and provides a very strong foundation for the rest of 2021 and beyond.

 » We look forward to further updates on sales growth through new product launches and ongoing international expansion efforts our existing activities. « 

Short term positions in small early stage ASX companies,
with high potential and short-term price catalysts.

Focused on resource exploration, early stage technology and biotechnology.

Exceptional opportunities in a wide range of
Early growth industries with strong management.

The aim is to achieve a return of 1,000% plus for medium to long-term investments.

Long-term positions in various industries.

Looking for a strong management where traction
is established and is in a growth phase.

S3 Consortium Pty Ltd (CAR # 433913) is an authorized corporate agent of LeMessurier Securities Pty Ltd (AFSL # 296877). The information contained in this article is for general information only. All advice is general advice only. Neither your personal goals, your financial situation nor your needs were taken into account. Accordingly, you should consider how adequately the advice (if any) fits these goals, financial situation and needs before following the advice.

S3 Consortium Pty Ltd does and seeks business with companies mentioned in its articles. As a result, investors should be aware that the company may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as a single factor in making an investment decision. The editors of this article also wish to disclose that they are permitted to hold this stock in their portfolios and that any decision to buy this stock should be made after the buyer has verified the validity of the information in this article.

The information contained in this article is current as of the final date. The information contained in this article is based on sources that S3 Consortium Pty Ltd can reasonably believe to be reliable and are publicly available. No “inside information” is ever obtained, disclosed or used by the S3 Consortium.

Founded seven years ago, is Australia’s leading and longest-running website for investor and financial news, education and expert opinion.

Finfeed was published by StocksDigital and was created to keep you updated on the coming and going every day Going to report on ASX-listed stocks in the small-cap market.

As the first digital publication dedicated specifically to this area, Finfeed soon became the most trusted publication on the market, quickly drawing over two million page views – a number that keeps rising. offers readers informative articles covering the latest market-moving #ASX small-cap news, as well as exclusive content you won’t find anywhere else. It is aimed at those interested in investing, market education, business performance, start-ups and much more. is the only media company operating under a financial services license and is supported by leading journalists and analysts with their own brands.

The website aims to inform, educate and entertain with content that exposes the heart of financial matters.

Finfeed is a premier source of investor and market intelligence, where everything investors need to know about investment opportunities is written in plain English.

Over the years, the website has grown from coverage only to Small Caps expanded to portray Australia’s leading ASX-listed small, mid and large caps, as well as some of the country’s most successful CEOs and corporate leaders, to find out what makes them tick.

The information on this website is general only Information. All advice is general advice only. Your personal goals, financial situation or needs were not taken into account. Accordingly, you should consider how adequately the advice (if any) fits these goals, financial situation and needs before following the advice. S3 Consortium Pty Ltd (CAR # 433913) is an authorized corporate agent of LeMessurier Securities Pty Ltd (AFSL # 296877).

Similar title :
Creso Pharma (ASX: CPH ) Shares Jump To Record Sales Growth
Creso Pharma Delivers Another Strong Quarter As Connecticut One Another strong quarter offers new market opportunities
Creso achieves record sales growth for the second quarter in a row



Donnez votre avis et abonnez-vous pour plus d’infos


Vidéo du jour: